MIB-725
Asset
Oral next-generation NAD+ precursor boosting cellular NAD+ levels.
- Stage
- Phase 1
- Modality
- Small molecule
- Target
- Oxidative phosphorylation
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Acute kidney injury
Phase 1, metrobiotech.com, 7 Oct 2026
In the full profile
- Targets and what it contains3
- Owner and partners1
- Trials1
- Evidence for its targets3
- Competitors12
- Aging relevance2
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026, 2 sources